Pharmaceuticals, Biotechnology and Life Sciences
The US Food and Drug Administration approved Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic cervical cancer with disease…
A clinical stage biopharmaceutical company, 4D pharma, pioneering the development of Live Biotherapeutic Products, has made a deal with a subsidiary of…
AstraZeneca and Merck have gotten EMA’s approval of Lynparza tablets for use twice daily, as a maintenance therapy for patients…
AstraZeneca and Merck will have a new Orphan Drug Designation in selumetinib, a MEK 1/2 inhibitor, as the US Food and…
Merck’s anti PD-1 therapy Keytruda has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) to treat…
AstraZeneca and Merck said Wednesday that th eUS Food and Drug Administration (FDA) has accepted and granted priority review for a…
AstraZeneca’s and Merck’s Lynparza new tablet’s formulation has been approved as maintenance treatment for women with platinum-sensitive recurrent ovarian cancer regardless of BRCA-mutation status, the companies said Friday.
AstraZeneca and Merck on Thursday said that they have made a deal to co-develop and co-commercialise AstraZeneca’s oncology product Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
NOXXON Pharma, a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, has treated first patients in its Phase 1/2 clinical trial in patients with metastatic colorectal and pancreatic cancer at the National Center for Tumor Diseases in Heidelberg, Germany.
Novartis and Merck have both surprised experts in the past week by finding new ways to tackle heart disease, although the jury remains out as to whether this scientific success will translate into blockbuster sales.